The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.50
Bid: 48.00
Ask: 49.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.083%)
Open: 48.50
High: 49.00
Low: 48.50
Prev. Close: 48.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

15 Feb 2016 07:00

RNS Number : 9846O
Cambridge Cognition Holdings PLC
15 February 2016
 

15th February 2016

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Directorate Change

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets computerised neuropsychological tests including those enabling the early detection of dementia, announces the appointment of Steven Powell as Chief Executive Officer ('CEO'). This confirms the role he accepted in July 2015 when the then CEO, Nick Kerton, took an extended leave of absence from the Company due to a serious medical condition.

 

With over 25 years of operational and investment experience in the pharmaceutical and life sciences sector, Steven joined the Company as Head of European Operations in 2014. In this position, he was heavily involved in the development and implementation of the current product strategy, which is now starting to establish the Company as the leading provider of point of care cognitive assessments for dementia. Since his appointment to the board as COO and Interim CEO in July 2015, he has driven that strategy forward successfully. As a result, the transition from COO to CEO has been a natural one under the circumstances.

 

Nick Kerton will remain as a Non-Executive Director continuing to support the Company with his extensive technical and market knowledge.

 

Non-Executive Chairman at Cambridge Cognition, Michael Lewis commented: "We would like to thank Nick for his significant contribution to the development of Cambridge Cognition and we are delighted that Steven has accepted the permanent role of CEO to continue the excellent work that he has been doing since July last year. I am sure that he will continue to develop our management team, evolve the strategy and take the business on to the next level."

 

Steven Powell, CEO of Cambridge Cognition, commenting on his new role: "I am delighted that I have the confidence of the board to lead the Company to the next phase of growth by implementing the plans that we have been formulating over the past year."  

 

 

Enquiries:

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Steven Powell, Chief Operating Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer

finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Geoff Nash/Simon Hicks

(Corporate Finance)

Malar Velaigam

(Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Lianne Cawthorne

Mob: 07584 391 303

Paul McManus

Mob: 07980 541 893

 

 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAMMGMZVZFGVZM
Date   Source Headline
26th Jul 20227:00 amRNSGrant of Options
22nd Jul 202211:05 amRNSSecond Price Monitoring Extn
22nd Jul 202211:00 amRNSPrice Monitoring Extension
22nd Jul 20227:00 amRNSDirector/PDMR Share Purchases
21st Jul 20227:00 amRNSTrading Update and Notice of Results
14th Jul 202211:06 amRNSSecond Price Monitoring Extn
14th Jul 202211:00 amRNSPrice Monitoring Extension
30th Jun 20225:43 pmRNSHolding(s) in Company
8th Jun 20223:14 pmRNSResult of AGM
16th May 20224:35 pmRNSPosting of Annual Report & Notice of AGM
12th Apr 20227:00 amRNSResults for the year ended 31 December 2021
6th Apr 20227:00 amRNSSenior Management Appointments
31st Mar 20227:00 amRNSNotice of Results
29th Mar 20222:06 pmRNSSecond Price Monitoring Extn
29th Mar 20222:00 pmRNSPrice Monitoring Extension
28th Mar 20224:41 pmRNSSecond Price Monitoring Extn
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 20227:00 amRNS£1 million contract for pivotal autoimmune trial
24th Mar 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
4th Feb 202212:06 pmRNSHolding(s) in Company
2nd Feb 20227:00 amRNS£2.1 million contract
27th Jan 20227:00 amRNSTrading Update
10th Jan 20227:00 amRNSNew Major Pharma Client for Schizophrenia Trials
16th Dec 20217:00 amRNSElectronic Clinical Outcomes Assessment Contract
9th Dec 20217:00 amRNS£1.0m Schizophrenia clinical trial contract
22nd Nov 202111:50 amRNSHolding(s) in Company
16th Nov 20217:00 amRNSGrant of Options
2nd Nov 20217:00 amRNSDirectorate Change
26th Oct 20217:00 amRNSContract for pivotal schizophrenia clinical trial
6th Oct 202110:06 amRNSHolding(s) in Company
21st Sep 20217:00 amRNSInterim Results
3rd Aug 20217:00 amRNSTrading Update and Notice of Results
9th Jul 20214:41 pmRNSSecond Price Monitoring Extn
9th Jul 20214:35 pmRNSPrice Monitoring Extension
9th Jul 20217:00 amRNS£1 million contract for late phase cancer trial
1st Jul 20217:00 amRNSSpin-out of Monument Therapeutics
28th Jun 20214:40 pmRNSSecond Price Monitoring Extn
28th Jun 20214:36 pmRNSPrice Monitoring Extension
28th Jun 20212:06 pmRNSSecond Price Monitoring Extn
28th Jun 20212:00 pmRNSPrice Monitoring Extension
28th Jun 202111:05 amRNSSecond Price Monitoring Extn
28th Jun 202111:00 amRNSPrice Monitoring Extension
28th Jun 20217:00 amRNSNew £2.2 million contract
14th Jun 20217:00 amRNS£1.4m of contracts for digital health & wearables
11th Jun 20217:00 amRNSBrain Health Registry Cognitive Assessment Partner
3rd Jun 20213:58 pmRNSHolding(s) in Company
2nd Jun 20217:00 amRNSAppointment of Executive Director
27th May 202112:58 pmRNSResult of AGM and Board Changes
5th May 20217:00 amRNSPosting of Annual Report & Notice of AGM
4th May 202111:52 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.